Biotech | December 24, 2021
Novavax and SK bioscience expand manufacturing agreement
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
Up to 100 million mRNA vaccine doses could be produced in Australia each year
The Uteshiya facility, licensed by Healthium, will exclusively manufacture Healthium’s arthroscopy portfolio, including patented products in India and U.S.
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
The US $ 192.5 mn US government contract will help fund the centre of excellence to boost the domestic supply of critically needed laboratory plastics
The new facility will provide an important boost to vaccine capacity in Africa
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Subscribe To Our Newsletter & Stay Updated
